7-Bromo-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one

7-Bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (CAS 105544-36-3) is a strategically fused bicyclic scaffold engineered for kinase inhibitor development and antibacterial drug discovery. This molecule integrates a pyrido[2,3-b][1,4]oxazinone core—a nitrogen-oxygen heterocyclic system prevalent in DNA gyrase inhibitors and anticancer agents—with a bromine substituent at the C7 position. The fused tricyclic-like architecture (pyridine + oxazine + lactam) provides a rigid planar structure ideal for π-stacking interactions within enzyme active sites, while the C7-bromo handle enables efficient Pd-catalyzed cross-coupling (Suzuki, Buchwald-Hartwig) for rapid SAR exploration. The lactam moiety (2-one) offers hydrogen-bonding capability critical for target binding affinity, and the oxazine oxygen modulates electronic distribution across the ring system. This intermediate is particularly valuable for constructing topoisomerase inhibitors, EGFR kinase inhibitors, and agrochemical actives where the pyrido-oxazinone motif enhances metabolic stability and selectivity. Manufactured with purity ≥98% under controlled conditions, it supports drug discovery programs requiring modular access to fused nitrogen-oxygen heterocycles with precise halogenation patterns.